Trastuzumab for the Treatment of Salivary Duct Carcinoma

OBJECTIVES. Salivary duct carcinoma (SDC) is a rare and aggressive malignancy with high mortality and poor response to treatment. A significant fraction of SDCs are HER2 positive. This retrospective review examines HER2 testing in SDC and the outcome of trastuzumab-based therapy in adjuvant and pall...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Limaye, Sewanti A., Posner, Marshall R., Krane, Jeffrey F., Fonfria, Maria, Lorch, Jochen H., Dillon, Deborah A., Shreenivas, Aditya V., Tishler, Roy B., Haddad, Robert I.
Format: Artigo
Idioma:Inglês
Publicat: AlphaMed Press 2013
Matèries:
Head and Neck Cancers
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3607526/
https://ncbi.nlm.nih.gov/pubmed/23429737
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0369
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars